FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:2085-2087 December 30, 1999 Number 27 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

In recent years maternal serum screening in the second trimester of pregnancy has become a routine part of prenatal care in the United States and other industrialized nations. Maternal serum screening is designed to identify women whose fetuses are at increased risk for congenital anomalies, including neural-tube defects, other open fetal abnormalities, trisomy 21, and trisomy 18. Most commonly, alpha-fetoprotein, unconjugated estriol, and either intact human chorionic gonadotropin or its ß subunit are measured in serum. Absolute values for these analytes are converted to multiples of the normal median for each gestational age and together used to modify the mother's . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.